Loss of a 20S proteasome activator in saccharomyces cerevisiae downregulates genes important for genomic integrity, increases DNA damage, and selectively sensitizes cells to agents with diverse mechanisms of action

G3: Genes, Genomes, Genetics

Volumn 2, Issue 8, 2012, Pages 943-959

  Doherty, Kevin M ^a,b   Pride, Leah D ^a,c   Lukose, James ^a   Snydsman, Brian E ^d   Charles, Ronald ^a   Pramanik, Ajay ^a   Muller, Eric G ^d   Botstein, David ^e   Moore, Carol Wood ^a,b  

^a CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c CITY COLLEGE OF NEW YORK   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e PRINCETON UNIVERSITY   (United States)

Author keywords

20S proteasome activator; BLM10 PA200; DNA damage; Molecular chaperones; UBP3 BLM3

Indexed keywords

ANTINEOPLASTIC AGENT; BLM10 PROTEIN, S CEREVISIAE; CHAPERONE; OXIDIZING AGENT; PROTEASOME; PROTEINASE; SACCHAROMYCES CEREVISIAE PROTEIN; UBP3 PROTEIN, S CEREVISIAE;

ARTICLE; CELL NUCLEUS; CHEMISTRY; DIPLOIDY; DNA DAMAGE; DOWN REGULATION; DRUG EFFECT; G2 PHASE CELL CYCLE CHECKPOINT; GENETICS; GENOMIC INSTABILITY; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; MUTATION; SACCHAROMYCES CEREVISIAE; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL NUCLEUS; DIPLOIDY; DNA DAMAGE; DOWN-REGULATION; ENDOPEPTIDASES; G2 PHASE CELL CYCLE CHECKPOINTS; GENOMIC INSTABILITY; M PHASE CELL CYCLE CHECKPOINTS; MOLECULAR CHAPERONES; MUTATION; OXIDANTS; PROTEASOME ENDOPEPTIDASE COMPLEX; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; UP-REGULATION;

EID: 84883572040     PISSN: None     EISSN: 21601836     Source Type: Journal    
DOI: 10.1534/g3.112.003376     Document Type: Article

References (101)

1. Aouida, M., N. Page, A. Leduc, M. Peter, and D. Ramotar, 2004 A genomewide screen in Saccharomyces cerevisiae reveals altered transport as a mechanism of resistance to the anticancer drug bleomycin. Cancer Res. 64: 1102-1109.
2. Awasthi, N., and B. J. Wagner, 2005 Upregulation of heat shock protein expression by proteasome inhibition: an antiapoptotic mechanism in the lens. Invest. Ophthalmol. Vis. Sci. 46: 2082-2091.
3. Bachmair, A., D. Finley, and A. Varshavsky, 1986 In vivo half-life of a protein is a function of its amino-terminal residue. Science 234: 179-186.
4. Baudin, A., O. Ozier-Kalogeropoulos, A. Denouel, F. Lacroute, and C. Cullin, 1993 A simple and efficient method for direct gene deletion in Saccharomyces cerevisiae. Nucleic Acids Res. 21: 3329-3330.
5. Baxter, B. K., and E. A. Craig, 1998 Isolation of UBP3, encoding a deubiquitinating enzyme, as a multicopy suppressor of a heat-shock mutant strain of S. cerevisiae. Curr. Genet. 33: 412-419.
6. Beaudouin, R., S. T. Lim, J. A. Steide, M. Powell, J. McKoy et al., 1993 Bleomycin affects cell wall anchorage of mannoproteins in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 37: 1264-1269.
7. Bennett, C. B., L. K. Lewis, G. Karthikeyan, K. S. Lobachev, Y. H. Jin et al., 2001 Genes required for ionizing radiation resistance in yeast. Nat. Genet. 29: 426-434.
8. Blickwedehl, J., S. McEvoy, I. Wong, P. Kousis, J. Clements et al., 2007 Proteasomes and proteasome activator 200 kDa (PA200) accumulate on chromatin in response to ionizing radiation. Radiat. Res. 167: 663-674.
9. Blickwedehl, J., M. Agarwal, C. Seong, R. K. Pandita, T. Melendy et al., 2008 Role for proteasome activator PA200 and postglutamyl proteasome activity in genomic stability. Proc. Natl. Acad. Sci. USA 105: 16165-16170.
10. Brauer, M. J., A. J. Saldanha, K. Dolinski, and D. Botstein, 2005 Homeostatic adjustment and metabolic remodeling in glucoselimited yeast cultures. Mol. Biol. Cell 16: 2503-2517.
11. Brauer, M. J., C. Huttenhower, E. M. Airoldi, R. Rosenstein, J. C. Matese et al., 2008 Coordination of growth rate, cell cycle, stress response, and metabolic activity in yeast. Mol. Biol. Cell 19: 352-367.
12. Brew, C. T., and T. C. Huffaker, 2002 The yeast ubiquitin protease, Ubp3p, promotes protein stability. Genetics 162: 1079-1089.
13. Brunton, L. L., J. S. Lazo, and K. L. Parker, editors, 2006 Goodman and Gilman's The Pharmacological Basis of Therapeutics. McGraw-Hill, New York.
14. Burger, H., A. Capelloa, P. W. Schenka, G. Stotera, J. Brouwerb et al., 2000 A genome-wide screening in Saccharomyces cerevisiae for genes that confer resistance to the anticancer agent cisplatin. Biochem. Biophys. Res. Commun. 269: 767-774.
15. Cloos, J., W. P. De Boer, M. H. Snel, P. Van Den Ijssel, B. Ylstra et al., 2006 Microarray analysis of bleomycin-exposed lymphoblastoid cells for identifying cancer susceptibility genes. Mol. Cancer Res. 4: 71-77.
16. Coughlan, C., and J. Brodsky, 2003 Yeast as a model system to investigate protein conformational diseases, pp. 77-90 in Protein Misfolding and Disease: Principles and Protocols, edited by P. Bross, and N. Gregersen. Humana Press Inc., Totowa, NJ.
17. Dange, T., D. Smith, T. Noy, P. C. Rommel, L. Jurzitza et al., 2011 Blm10 protein promotes proteasomal substrate turnover by an active gating mechanism. J. Biol. Chem. 286: 42830-42839.
18. Davermann, D., M. Martinez, J. McKoy, N. Patel, D. Averbeck et al., 2002 Impaired mitochondrial function protects against free radicalmediated cell death. Free Radic. Biol. Med. 33: 1209-1220.
19. Deans, A. J., and S. C. West, 2011 Mitomycin C DNA interstrand crosslink repair and cancer. Nat. Rev. Cancer 11: 467-480.
20. Demartino, G. N., and T. G. Gillette, 2007 Proteasomes: machines for all reasons. Cell 129: 659-662.
21. Demple, B., and L. Harrison, 1994 Repair of oxidative damage to DNA: enzymology and biology. Annu. Rev. Biochem. 63: 915-948.
22. Dobson, C. M., 2003 Protein folding and misfolding. Nature 426: 884-890.
23. Doherty, K., A. Pramanik, L. Pride, J. Lukose, and C. W. Moore, 2004 Expression of the expanded YFL007w ORF and assignment of the gene name BLM10. Yeast 21: 1021-1023.
24. Edwards, C. M., S. T. Lwin, J. A. Fowler, B. O. Oyajobi, J. Zhuang et al., 2009 Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo. Am. J. Hematol. 84: 268-272.
25. Febres, D. E., A. Pramanik, M. Caton, K. Doherty, J. McKoy et al., 2001 The novel BLM3 gene encodes a protein that protects against lethal effects of oxidative damage. Cell Mol Biol (Noisy-le-grand) 47: 1149-1162.
26. Fehlker, M., P. Wendler, A. Lehmann, and C. Enenkel, 2003 Blm3 is part of nascent proteasomes and is involved in a late stage of nuclear proteasome assembly. EMBO Rep. 4: 959-963.
27. Finley, D., 2009 Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu. Rev. Biochem. 78: 477-513.
28. Forster, A., and C. P. Hill, 2006 Proteasome activators, pp. 89-110 in Protein Degradation: The Ubiquitin-Proteasome System, edited by R. J. Mayer, A. Ciechanover, andM. Rechsteiner. Wiley-VCH Verlag GmbH & Co., KGaA, Weinheim, Germany.
29. Friedberg, E. C., G. C. Walker, W. Siede, R. D. Wood, R. A. Schultz et al., 2006 DNA Repair and Mutagenesis, Ed. 2. American Society for Microbiology Press, Washington, DC.
30. Gietz, R. D., and R. A. Woods, 2002 Transformation of yeast by lithium acetate/single-stranded carrier DNA/polyethylene glycol method, pp. 87-96 in Methods in Enzymology, edited by C. Guthrie, and G. R. Fink. Academic Press, Inc., San Diego, California.
31. Gilbert, C. S., M. Van Den Bosch, C. M. Green, J. E. Vialard, M. Grenon et al., 2003 The budding yeast Rad9 checkpoint complex: chaperone proteins are required for its function. EMBO Rep. 4: 953-958.
32. Glickman, M. H., and D. Raveh, 2005 Proteasome plasticity. FEBS Lett. 579: 3214-3223.
33. Goldberg, A. L., 2003 Protein degradation and protection against misfolded or damaged proteins. Nature 426: 895-899.
34. Gollub, J., C. A. Ball, G. Binkley, J. Demeter, D. B. Finkelstein et al., 2003 The Stanford Microarray Database: data access and quality assessment tools. Nucleic Acids Res. 31: 94-96.
35. Hardwick, J. S., F. G. Kuruvilla, J. K. Tong, A. F. Shamji, and S. L. Schreiber, 1999 Rapamycin-modulated transcription defines the subset of nutri-ent-sensitive signaling pathways directly controlled by the Tor proteins. Proc. Natl. Acad. Sci. USA 96: 14866-14870.
36. Henikoff, J. G., E. A. Greene, S. Pietrokovski, and S. Henikoff, 2000 Increased coverage of protein families with the blocks database servers. Nucleic Acids Res. 28: 228-230.
37. Hideshima, T., P. Richardson, D. Chauhan, V. J. Palombella, P. J. Elliott et al., 2001 The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61: 3071-3076.
38. Ho, Y., A. Gruhler, A. Heilbut, G. D. Bader, L. Moore et al., 2002 Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature 415: 180-183.
39. Huo, Q., 2010 Protein complexes/aggregates as potential cancer biomarkers revealed by a nanoparticle aggregation immunoassay. Colloids Surf. B Biointerfaces 78: 259-265.
40. Iwanczyk, J., K. Sadre-Bazzaz, K. Ferrell, E. Kondrashkina, T. Formosa et al., 2006 Structure of the Blm10-20 S proteasome complex by cryo-electron microscopy. Insights into the mechanism of activation of mature yeast proteasomes. J. Mol. Biol. 363: 648-659.
41. Jakob, C., K. Egerer, P. Liebisch, S. Turkmen, I. Zavrski et al., 2007 Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood 109: 2100-2105.
42. Kajava, A. V., C. Gorbea, J. Ortega, M. Rechsteiner, and A. C. Steven, 2004 New HEAT-like repeat motifs in proteins regulating proteasome structure and function. J. Struct. Biol. 146: 425-430.
43. Khor, B., A. L. Bredemeyer, C. Y. Huang, I. R. Turnbull, R. Evans et al., 2006 Proteasome activator PA200 is required for normal spermatogenesis. Mol. Cell. Biol. 26: 2999-3007.
44. Krogan, N. J., M. H. Lam, J. Fillingham, M. C. Keogh, M. Gebbia et al., 2004 Proteasome involvement in the repair of DNA double-strand breaks. Mol. Cell 16: 1027-1034.
45. Kubitschek, H. E., 1970 Introduction to Research With Continuous Cultures, Prentice Hall, Englewood Cliffs, NJ.
46. Lehmann, A., K. Jechow, and C. Enenkel, 2008 Blm10 binds to pre-activated proteasome core particles with open gate conformation. EMBO Rep. 9: 1237-1243.
47. Lewis, L. K., and M. A. Resnick, 2000 Tying up loose ends: nonhomologous end-joining in Saccharomyces cerevisiae. Mutat. Res. 451: 71-89.
48. Li, X., A. R. Kusmierczyk, P. Wong, A. Emili, and M. Hochstrasser, 2007 beta-Subunit appendages promote 20S proteasome assembly by overcoming an Ump1-dependent checkpoint. EMBO J. 26: 2339-2349.
49. Lopez, A. D., K. Tar, U. Krügel, T. Dange, I. G. Ros et al., 2011 Proteasomal degradation of Sfp1 contributes to the repression of ribosome biogenesis during starvation and is mediated by the proteasome activator Blm10. Mol. Biol. Cell 22: 528-540.
50. Ma, X. J., Q. Lu, and M. Grunstein, 1996 A search for proteins that interact genetically with histone H3 and H4 amino termini uncovers novel regulators of the Swe1 kinase in Saccharomyces cerevisiae. Genes Dev. 10: 1327-1340.
51. Mao, P., and M. J. Smerdon, 2010 Yeast deubiquitinase Ubp3 interacts with the 26 S proteasome to facilitate Rad4 degradation. J. Biol. Chem. 285: 37542-37550.
52. Marques, A. J., C. Glanemann, P. C. Ramos, and R. J. Dohmen, 2007 The C-terminal extension of the beta7 subunit and activator complexes stabilize nascent 20 S proteasomes and promote their maturation. J. Biol. Chem. 282: 34869-34876.
53. Martin, S. G., T. Laroche, N. Suka, M. Grunstein, and S. M. Gasser, 1999 Relocalization of telomeric Ku and SIR proteins in response to DNA strand breaks in yeast. Cell 97: 621-633.
54. Martzen, M. R., S. M. McCraith, S. L. Spinelli, F. M. Torres, S. Fields et al., 1999 A biochemical genomics approach for identifying genes by the activity of their products. Science 286: 1153-1155.
55. Mascorro-Gallardo, J. O., A. A. Covarrubias, and R. Gaxiola, 1996 Construction of a CUP1 promoter-based vector to modulate gene expression in Saccharomyces cerevisiae. Gene 172: 169-170.
56. McCullock, S., T. Kinard, L. McCullough, and T. Formosa, 2006 blm3-1 is an allele of UBP3, a ubiquitin protease that appears to act during transcription of damaged DNA. J. Mol. Biol. 363: 660-672.
57. Mitsiades, N., C. S. Mitsiades, V. Poulaki, D. Chauhan, G. Fanourakis et al., 2002 Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. USA 99: 14374-14379.
58. Moazed, D., and D. Johnson, 1996 A deubiquitinating enzyme interacts with SIR4 and regulates silencing in S. cerevisiae. Cell 86: 667-677.
59. Moore, C. W., 1978 Responses of radiation-sensitive mutants of Saccharomyces cerevisiae to lethal effects of bleomycin. Mutat. Res. 51: 165-180.
60. Moore, C. W., 1982 Control of in vivo (cellular) phleomycin sensitivity by nuclear genotype, growth phase, and metal ions. Cancer Res. 42: 929-933.
61. Moore, C. W., 1988 Internucleosomal cleavage and chromosomal degradation by bleomycin and phleomycin in yeast. Cancer Res. 48: 6837-6843.
62. Moore, C. W., 1990 Degradation of DNA and structure-activity relationship between bleomycins A2 and B2 in the absence of DNA repair. Biochemistry 29: 1342-1347.
63. Moore, C. W., 1991 Further characterizations of bleomycin-sensitive (blm) mutants of Saccharomyces cerevisiae with implications for a radiomimetic model. J. Bacteriol. 173: 3605-3608.
64. Moore, C. W., 1999 Bleomycin, pp. 292-297 in Encyclopedia of Molecular Biology, edited by T. E. Creighton. John Wiley and Sons, Inc., New York.
65. Moore, C. W., R. Del Valle, J. McKoy, A. Pramanik, and R. E. Gordon, 1992 Lesions and preferential initial localization of [S-methyl-3H] bleomycin A2 on Saccharomyces cerevisiae cell walls and membranes. Antimicrob. Agents Chemother. 36: 2497-2505.
66. Moore, C. W., J. McKoy, M. Dardalhon, D. Davermann, M. Martinez et al., 2000 DNA damage-inducible and RAD52-independent repair of DNA double-strand breaks in Saccharomyces cerevisiae. Genetics 154: 1085-1099.
67. Moore, C. W., J. McKoy, R. Del Valle, D. Armstrong, E. M. Bernard et al., 2003 Fungal cell wall septation and cytokinesis are inhibited by bleomycins. Antimicrob. Agents Chemother. 47: 3281-3289.
68. Muller, E. G., B. E. Snydsman, I. Novik, D. W. Hailey, D. R. Gestaut et al., 2005 The organization of the core proteins of the yeast spindle pole body. Mol. Biol. Cell 16: 3341-3352.
69. Myers, C. L., D. Robson, A. Wible, M. A. Hibbs, C. Chiriac et al., 2005 Discovery of biological networks from diverse functional genomic data. Genome Biol. 6: R114.
70. Nagaraj, N. S., O. V. Singh, and N. B. Merchant, 2010 Proteomics: a strategy to understand the novel targets in protein misfolding and cancer therapy. Expert Rev. Proteomics 7: 613-623.
71. J. L. Nitiss, and J. Heitman, editors, 2007 Yeast as a Tool in Cancer Research. Springer, Dordrecht, The Netherlands.
72. Orlowski, R. Z., and D. J. Kuhn, 2008 Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin. Cancer Res. 14: 1649-1657.
73. Ortega, J., J. B. Heymann, A. V. Kajava, V. Ustrell, M. Rechsteiner et al., 2005 The axial channel of the 20S proteasome opens upon binding of the PA200 activator. J. Mol. Biol. 346: 1221-1227.
74. Pan, X., P. Ye, D. S. Yuan, X. Wang, J. S. Bader et al., 2006 A DNA integrity network in the yeast Saccharomyces cerevisiae. Cell 124: 1069-1081.
75. Parsons, A. B., R. L. Brost, H. Ding, Z. Li, C. Zhang et al., 2004 Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. Nat. Biotechnol. 22: 62-69.
76. Prein, B., K. Natter, and S. D. Kohlwein, 2000 A novel strategy for constructing N-terminal chromosomal fusions to green fluorescent protein in the yeast Saccharomyces cerevisiae. FEBS Lett. 485: 29-34.
77. Pritts, T. A., E. S. Hungness, D. D. Hershko, B. W. Robb, X. Sun et al., 2002 Proteasome inhibitors induce heat shock response and increase IL-6 expression in human intestinal epithelial cells. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282: R1016-R1026.
78. Reinhardt, C. G., and T. R. Krugh, 1978 A comparative study of ethidium bromide complexes with dinucleotides and DNA: direct evidence for intercalation and nucleic acid sequence preferences. Biochemistry 17: 4845-4854.
79. Rose, M., and D. Botstein, 1983 Construction and use of gene fusions to lacZ (beta-galactosidase) that are expressed in yeast. Methods Enzymol. 101: 167-180.
80. Rose, M. D., and J. R. Broach, 1991 Cloning genes by complementation in yeast. Methods Enzymol. 194: 195-230.
81. Rosenzweig, R., and M. H. Glickman, 2008 Chaperone-driven proteasome assembly. Biochem. Soc. Trans. 36: 807-812.
82. Russell, S. J., K. A. Steger, and S. A. Johnston, 1999 Subcellular localization, stoichiometry, and protein levels of 26 S proteasome subunits in yeast. J. Biol. Chem. 274: 21943-21952.
83. Sadre-Bazzaz, K., F. G. Whitby, H. Robinson, T. Formosa, and C. P. Hill, 2010 Structure of a Blm10 complex reveals common mechanisms for proteasome binding and gate opening. Mol. Cell 37: 728-735.
84. Sakano, K., S. Oikawa, K. Hasegawa, and S. Kawanishi, 2001 Hydroxyurea induces site-specific DNA damage via formation of hydrogen peroxide and nitric oxide. Jpn. J. Cancer Res. 92: 1166-1174.
85. Savulescu, A. F., and M. H. Glickman, 2011 Proteasome ativator 200: the HEAT is on.. Mol. Cellular Proteomics 10: R110.006890.
86. Schmidt, M., W. Haas, B. Crosas, P. G. Santamaria, S. P. Gygi et al., 2005a The HEAT repeat protein Blm10 regulates the yeast proteasome by capping the core particle. Nat. Struct. Mol. Biol. 12: 294-303.
87. Schmidt, M., J. Hanna, S. Elsasser, and D. Finley, 2005b Proteasomeassociated proteins: regulation of a proteolytic machine. Biol. Chem. 386: 725-737.
88. Scott, M., and J. Frydman, 2003 Aberrant protein folding as the molecular basis of cancer, pp. 67-76 in Protein Misfolding and Disease: Principles and Protocols, edited by P. Bross, and N. Gregersen. Humana Press Inc., Totowa, NJ.
89. Sealfon, R. S., M. A. Hibbs, C. Huttenhower, C. L. Myers, and O. G. Troyanskaya, 2006 GOLEM: an interactive graph-based gene-ontology navigation and analysis tool. BMC Bioinformatics 7: 443-451.
90. SGD Project, 2010 Saccharomyces Genome Database. Available at: http://www.yeastgenome.org/July14,.
91. Shimogawa, M. M., M. M. Wargacki, E. G. Muller, and T. N. Davis, 2010 Laterally attached kinetochores recruit the checkpoint protein Bub1, but satisfy the spindle checkpoint. Cell Cycle 9: 3619-3628.
92. Stadtmueller, B. M., and C. P. Hill, 2011 Proteasome activators. Mol. Cell 41: 8-19.
93. Turner, M., D. Everman, S. Ellington, and C. Fields, 1990 Detection of free radicals during the cellular metabolism of adriamycin. Free Radic. Biol. Med. 9: 415-421.
94. Ustrell, V., L. Hoffman, G. Pratt, and M. Rechsteiner, 2002 PA200, a nuclear proteasome activator involved in DNA repair. EMBO J. 21: 3516-3525.
95. Van Den Bosch, M., and N. F. Lowndes, 2004 Remodelling the Rad9 checkpoint complex: preparing Rad53 for action. Cell Cycle 3: 119-122.
96. Voorhees, P. M., and R. Z. Orlowski, 2006 The proteasome and proteasome inhibitors in cancer therapy. Annu. Rev. Pharmacol. Toxicol. 46: 189-213.
97. Wada, M., M. Kosaka, S. Saito, T. Sano, K. Tanaka et al., 1993 Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance. J. Lab. Clin. Med. 121: 215-223.
98. Wyttenbach, A., J. Carmichael, J. Swartz, R. A. Furlong, Y. Narain et al., 2000 Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. USA 97: 2898-2903.
99. Yang, Y., J. Kitagaki, H. Wang, D. X. Hou, and A. O. Perantoni, 2009 Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci. 100: 24-28.
100. Yu, Y., Y. W. Jiang, R. J. Wellinger, K. Carlson, J. M. Roberts et al., 1996 Mutations in the homologous ZDS1 and ZDS2 genes affect cell cycle progression. Mol. Cell. Biol. 16: 5254-5263.
101. Zaarur, N., V. L. Gabai, J. A. Porco Jr, S. Calderwood, and M. Y. Sherman, 2006 Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors. Cancer Res. 66: 1783-1791.